Drug Profile


Alternative Names: JNJ-42847922; MIN-202

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janssen Research & Development
  • Class Antidepressants; Sleep disorder therapies
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia
  • Phase I Major depressive disorder

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 03 Aug 2017 Minerva Neurosciences plans to initiate three phase IIb trials of seltorexant, including two trials in Major depressive disorder and one trial in Insomnia without neuropsychiatric comorbid symptoms
  • 31 May 2017 Minerva plans three phase IIb trials for Major depressive disorder and Insomnia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top